Rabies antibody levels in bat handlers in the United Kingdom - Immune response before and after purified chick embryo cell rabies booster vaccination

被引:16
作者
Morris, Jill
Crowcroft, Natasha S.
Fooks, Anthony R.
Brookes, Sharon M.
Andrews, Nick
机构
[1] Hlth Protect Agcy, Ctr Infect, Immunisat Dept, London NW9 5HT, England
[2] Vet Lab Agcy, Rabies & Wildlife Zoonoses Grp, Weybridge, Surrey, England
[3] WHO, Collaborating Ctr Characterisat Rabies & Rabies R, Surrey, England
[4] Hlth Protect Agcy, Ctr Infect, Dept Stat, London NW9 5HT, England
来源
HUMAN VACCINES | 2007年 / 3卷 / 05期
关键词
bat workers; booster vaccination; cross-sectional survey; rabies vaccination; serology;
D O I
10.4161/hv.3.5.4216
中图分类号
Q81 [生物工程学(生物技术)]; Q93 [微生物学];
学科分类号
071005 ; 0836 ; 090102 ; 100705 ;
摘要
Periodic rabies booster injections are recommended for persons who are at continued risk of rabies exposures, but literature on booster intervals is not comprehensive. We recruited bat workers who received rabies vaccinations between September 2002 and March 2003 either as a primary rabies vaccination course (primary group) or rabies booster vaccination (secondary group). From September 2004, those bat workers in the primary group had two blood tests to determine their rabies antibody level; one immediately prior to their first booster vaccination and one approximately one month after the booster vaccination. Bat workers in the secondary group had one blood test, approximately two years after their last booster vaccination. Overall, 185 bat workers participated in the study: 145 in the primary group, 40 in the secondary group. Sixteen (11.1%) in the primary group were below the minimum recognized rabies antibody level of 0.5 IU/ml prior to their first booster vaccination; all were above this level one-month after their booster. All bat workers in the secondary group had a rabies antibody level above 0.5 IU/ml. In the primary group, age of the bat worker at primary immunization and rabies vaccine type were significantly associated with antibody response to the rabies booster. We recommend that the first rabies booster vaccination is given one year after the primary course and subsequent boosters are given every three to five years thereafter.
引用
收藏
页码:165 / 170
页数:6
相关论文
共 17 条
[1]   PREEXPOSURE IMMUNIZATION WITH INTRADERMAL HUMAN-DIPLOID CELL RABIES VACCINE - RISKS AND BENEFITS OF PRIMARY AND BOOSTER VACCINATION [J].
BERNARD, KW ;
MALLONEE, J ;
WRIGHT, JC ;
REID, FL ;
MAKINTUBEE, S ;
PARKER, RA ;
DWYER, DM ;
WINKLER, WG .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1987, 257 (08) :1059-1063
[2]  
Botvinkin A. D., 2005, Rabies Bulletin Europe, V29, P5
[3]   Safety and immunogenicity of Lyssavac Berna human diploid cell rabies vaccine in healthy adults [J].
Briggs, DJ ;
Dreesen, DW ;
Morgan, P ;
Chin, JE ;
Seedle, CD ;
Cryz, L ;
Gluck, R ;
Cryz, SJ .
VACCINE, 1996, 14 (14) :1361-1365
[4]   Rabies human diploid cell vaccine elicits cross-neutralising and cross-protecting immune responses against European and Australian bat lyssaviruses [J].
Brookes, SM ;
Parsons, G ;
Johnson, N ;
McElhinney, LM ;
Fooks, AR .
VACCINE, 2005, 23 (32) :4101-4109
[5]   Development of a fluorescent antibody virus neutralisation test (FAVN test) for the quantitation of rabies-neutralising antibody [J].
Cliquet, F ;
Aubert, M ;
Sagné, L .
JOURNAL OF IMMUNOLOGICAL METHODS, 1998, 212 (01) :79-87
[6]  
*DEP, 2005, IMM INF DIS 1996 GRE
[7]  
*DEP HLTH, 2002, RAB BAT HANDL VACC
[8]   2-YEAR COMPARATIVE TRIAL ON THE IMMUNOGENICITY AND ADVERSE-EFFECTS OF PURIFIED CHICK-EMBRYO CELL RABIES VACCINE FOR PRE-EXPOSURE IMMUNIZATION [J].
DREESEN, DW ;
FISHBEIN, DB ;
KEMP, DT ;
BROWN, J .
VACCINE, 1989, 7 (05) :397-400
[9]   European bat lyssaviruses: an emerging zoonosis [J].
Fooks, AR ;
Brookes, SM ;
Johnson, N ;
McElhinney, LM ;
Hutson, AM .
EPIDEMIOLOGY AND INFECTION, 2003, 131 (03) :1029-1039
[10]   EFFECTIVENESS AND TOLERANCE OF PRE- AND POSTEXPOSURE TREATMENT WITH PURIFIED INACTIVATED RABIES VACCINE PREPARED ON VERO CELL-LINE [J].
KLIETMANN, W ;
KLIETMANN, B ;
COX, J ;
CHARBONNIER, C .
VACCINE, 1988, 6 (01) :39-43